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ABSTRACT 
DEGENERATIVE AND COMPENSATORY FEATURES IN THE STRIATUM OF 
MPTP-TREATED MICE 
By Reza Ehsanian 
This study focuses on the time course of damage and compensatory ultrastractural 
changes associated with Parkinson's disease, as induced by a 35 mg/kg dose of 1-methyl-
4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) in C57BL/6 mice. The results suggested 
continued deterioration of the striatum up to 7 days post-injection of the MPTP, with 
notable recovery at 21 days post-injection. Dark terminals (DTs) were observed at 3, 7, 
and 21 days post-injection, with the highest frequencies occurring at 7 days post-
injection. The morphology of DTs indicates that they may contribute to the recovery of 
the animal. At 21 days post-injection, a point when behavioral and neurochemical 
recovery is expected to be nearly complete, there was a dramatic increase in healthy 
axons. The increase in axonal frequency at 21 days is indirect structural evidence for 
dopaminergic neuronal sprouting or some other regenerative process that would likely 
allow the mouse brain to compensate for previously eliminated neurons. 
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INTRODUCTION 
History 
Although, the most famed description of Parkinson's disease (PD) is attributed to 
James Parkinson, who described the disease in 1817, it was recognized long before then. 
Ancient Egyptians (1350-1200 BC) suggested the occurrence of parkinsonism in old age 
(Forno, 1996), while later observations of the disease were also documented by Leonardo 
da Vinci sometime between 1489 and 1506 (Calne et al., 1989). Charcot's lectures and 
observations give detailed descriptions of the manifestations of the disease (Charcot, 
1877). These early observations undoubtedly led to the work by the British physician 
Parkinson, who gave a nearly complete description of the disease he termed "paralysis 
agitans" (shaking palsy) (Parkinson, 1955), now called PD. 
Disease Frequency 
PD is the most common cause of parkinsonism, a term that refers to a syndrome of 
muscle rigidity, tremor, bradykinesia, and akinesia. PD is one of the most commonly 
encountered neurological disorders in clinical practice (MacDonald et al., 2000). From 
birth, the lifetime risk of developing PD is about 2% for men and 1.3% for women, while 
that for parkinsonism is slightly higher (4.4% for men and 3.7% for women); for both, the 
risk factor increases with age (Elbaz et al., 2002). The annual incidence of PD ranges 
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from 110 to 330 per 100,000 individuals over 50 years of age (Bower et al., 1999). For 
individuals over 65, the prevalence of PD has been estimated at 1800 per 100,000 
individuals. The incidence in those 85 to 89 years old increases 4.3 times to 2600 per 
100,000 over that in individuals 65 to 69 years old, in whom incidence is 600 per 100,000 
(de Rijk et al., 2000). When these statistics are considered in light of our increasing life 
spans, the need is amplified for basic scientific research investigating the degenerative 
and compensatory mechanisms involved in PD in hopes of finding potential targets for 
therapy. 
Clinical-Pathological Description 
PD is clinically defined as a distinctive progressive disorder characterized by 
asymmetric onset of the cardinal motor signs of resting tremor, rigidity, bradykinesia, and 
postural instability. A number of other clinical findings, such as masked face and 
festinating gait, occur less consistently (Calne, 1992; Forno, 1996; Gibb & Lees, 1988; 
Hughes, 1992; Larsen, 1994; Ward & Gibb, 1990). Nonmotor clinical features include 
dementia (Brown et al., 1984; Cummings et al., 1988; Mortimer et al., 1985; Rajput et al., 
1992), depression (Mayeux, 1992; Tandberg et al., 1996), hallucinations (Celesia et al., 
1972), and autonomic dysfunction (Quinn, 1989; Tanner et a l , 1992) as well as 
abnormalities in olfactory and visual perception (Langston, 2006). These signs of PD are 
accompanied by progressive neuropsychological impairment (Dubois & Pillon, 1997; 
Langston, 2006) that includes abnormal emotion processing (Benke et al., 1998; Blonder 
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et al., 1989; Borod ct al., 1990, Brekenstein et al , 2001; Langston, 2006; Pell, 1996). 
The average duration of illness is nine years (Hely et al., 1999). Patients with late onset 
PD and/or those whose disease is accompanied by dementia have short survival periods. 
Patients with tremor-dominant disease have a longer survival period than those with the 
akinetic form (Jellinger et al., 2002). 
The pathology responsible for the clinical conditions is accompanied by a reduction in 
dopamine levels in the striatum (Hornykiewicz, 2008; Kish et al., 1988; Langston et al., 
1992; Tetrad & Langston, 1989) and severe degeneration of dopaminergic neurons in the 
substantia nigra pars compacta (Forno, 1969; Langston et al., 1992; Tetrad & Langston, 
1989). The cardinal symptoms are observed once the striatal dopamine levels decrease 
by 60-80% (Bernheimer et al., 1973; Hornykiewicz and Kish, 1987). The fact that 
patients show few symptoms despite extreme dopamine reduction (< 60% of normal) 
suggests the existence of compensatory mechanisms in the remaining dopaminergic 
neurons (Bezard and Gross, 1998; Hornykiewicz, 1993, 2008). Therefore, it is clear that 
an understanding of the mechanisms of compensation in an accurate animal model that 
mimics this loss of dopaminergic neurons will lead to a better understanding of the 
progression of the disease. Cell losses also extend into extranigral sites, such as the locus 
coeraleus, the cholinergic nucleus basalis of Meynert, and frequently in the dorsal motor 
nucleus of the vagus (Forno, 1996; Forno et al., 1986; Markham & Diamond, 1993). 
Although these sites may play a role in the development of symptoms, our focus 
remained on the site most directly implicated in the development of PD, the striatum. 
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Lewy Bodies 
Formation of Lewy bodies and Lewy neurites within the substantia nigra is considered 
a pathological marker for the clinical condition in humans (Jellinger, 1987; Lewy, 1912; 
Lowe et al., 1997). Lewy bodies are also observed within the dot sal motor nucleus of the 
vagus, hypothalamus, cholinergic nucleus basalis of Meynert (Lewy, 1912, 1923; Obrrm 
& Ikuta, 1976). locus coeruleus, Edinger-Westphal nucleus in the midbrain, raphe nuclei, 
cerebral cortex (Fomo, 1996; Hughes et al., 1993), olfactory bulb (Reyes et al., 1992), 
cranial nerve motor nuclei, and central and peripheral divisions of the autonomic ganglia 
(Jager & Bethlem, 1960; Iwanaga et al , 1999; Wakabayahi & Takahashi, 1997). 
In 1997, a mutation was identified in the a-synuclein gene in families with autosomal 
dominant PD (Polymeropoulos et al , 1997). This form of PD (familial PD) is a variant 
of age-related, apparently nonhereditary (sporadic) PD that attacks people as early as in 
their 30s and has a strong hereditary component. This discovery, along with an earlier 
confirmation of the presence of Lewy bodies accompanying neural degeneration in 
individuals with familial PD (Golbe et al., 1990), led to pathohistological and molecular 
pathological identification of PD. Abnormal filaments in Lewy bodies are recognized by 
antibodies against a-synuclein in both familial and sporadic PD (Arima et al., 1998; Baba 
et al., 1998; Irizarry et al., 1998; Spillantini et al., 1997; Taeka et al., 1998; Wakabayahi 
et al., 1997; Wakabayashi et al., 1998). While Lewy bodies are considered to be reliable 
markers of neurodegeneration, they may not be present in the substantia nigra of all PD 
sufferers (Forno, 1996). In addition, the status of Lewy bodies as markers for 
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presymptomatic PD has been brought into question by reports documenting the presence 
of Lewy bodies in postmortem specimens from asymptomatic individuals (Gibb., 1988; 
Gibb, 1993; Forno, 1996). Therefore, although Lewy bodies do not occur in the mouse 
model of PD, the importance of the model cannot be disregarded due to the absence of 
Lewy bodies. 
MPTP-Mouse Model 
The MPTP model (Langston, 1995) has been one of the most accurate models of 
human idiopathic PD and has contributed to the understanding of the course and cause of 
PD. MPTP is a neurotoxin accidentally developed in humans (Forno, 1996) that targets 
the dopaminergic neurons within the nigrostriatal tract and produces an array of clinical 
and pathological features that nearly duplicates that of idiopathic PD. 
MPTP induces parkinsonian symptoms in various animals, including the strain of 
mice used in this study (Langston et al., 1984,1992; Lewin, 1986; Tetrud & Langston, 
1989). Of the different studies implementing the mouse model (Edwards, 1993; Irwin el 
al., 1992; Riachi & Harik, 1Y988; Sundstrom et al., 1988), older mice (>8 weeks) of the 
strain C57BL/6 appear to be the most responsive to the initial neurotoxic effects of the 
MPTP. The mouse brain is purged of MPTP in a shorter period of time than in the brain 
of the primate (Edwards, 1993; Riachi & Harik, 1988). This reduction in neurotoxic 
insult may allow for increases in synaptic output (Cochiolo et al., 2000) and regrowth of 
injured nerve fibers (Ricaurte et al., 1986; Sundstrom et al , 1987) to restore dopamine 
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production to near normal levels (Hallman et al,, 1985; Reinhard et al., 1988b; Ricaurte et 
al., 1986; Sundstrom et al., 1990) and allow for the behavioral recovery observed in mice 
(Hallman et al., 1984; Willis and Donnan, 1987). This clearing may also explain the fact 
that mice in general are more highly resistant to MPTP than are primates, requiring 
higher doses for comparable effects (Edwards, 1993). Due to the mouse's robust nature 
and ability to recover from MPTP-induced parkinsonism, the mouse model is one of 
particular interest in the study of compensatory pathways arising after MPTP treatment. 
As in human PD, the MPTP-treated mouse has been shown to suffer substantial 
depletion of striatal dopamine (Irwin, Langston, & DeLanney, 1987; Irwin et al., 1992; 
Reinhard et al., 1988b). Several laboratories have reported severe lesions of the 
substantia nigra in mice, with cell deaths comparable in number to those in primates 
(Cochiolo et al , 2000; Heikkila et al., 1984a; Sundstrom et al., 1987,1988,1990). In the 
most critical aspects of true parkinsonism, the neurochemical and neuropathological 
syndrome induced in the C57BL/6 strain of older mice by MPTP corresponds to that 
arising from human PD. Therefore, the MPTP-treated C57BL/6 mouse older than 12 
weeks serves as an adequate model to study the degenerative and compensatory effects of 
MPTP-induced neurodegeneration. 
Site and Mmode of MPTP Action 
The site and mode of action of MPTP have been heavily investigated. Evidence 
indicates that MPTP enters the glial cells in the striatum or the substantia nigra, where it 
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is cleaved by the monoamine oxidase-B isozyme to form MPP+ (l-methyl-4-
phenylpyridinium), the neurotoxic metabolite (Chiba et al., 1985; Giovanni et al., 1991; 
Javitch & Snyder, 1985; Ransom et al., 1987; Riachi & Harik, 1988). Striatal MPP+is 
then taken up through the dopamine transporter of dopaminergic neurons and routed in a 
retrograde fashion to the cell bodies (Chiba et al., 1985; Markham & Diamond, 1993). 
There is little doubt that MPP+ is imported into mitochondria where it binds to NADH 
dehydrogenase in complex I of the oxidative electron transport chain (Mizumo et al., 
1989; Parker et al., 1989; Ramsay & Singer, 1986; Ramsay et al., 1991) inhibiting 
mitochondrial respiration (Ramsay et al., 1986, 1987). Oxidative stress is also increased 
through the production of toxic free radicals (Adams et al., 1986; Corsini et al., 1985; 
Cleeter et al., 1992; Hasegawa et al., 1990; Johannessen et al., 1986; Perry et al., 1985; 
Rossetti et a l , 1988; Sinha et al., 1986). 
Compensatory Increase in Dopamine Output in Response to Nigrostriatal Lesioning 
Since the early postmortem analyses of dopaminergic neurons and dopamine levels in 
PD, a causal relation has been proposed between the extended preclinical phase of the 
disease and the elevated ratio of dopamine metabolites to dopamine. Dopaminergic 
metabolites, such as homo vanillic acid (Bernheimer and Hornykiewicz, 1965; 
Hornykiewicz, 1993) and dihydroxyphenylacetic acid (Zigmond and Strieker, 1977; 
Zigmond et al., 1984), increase in striatal extracts in relation to dopamine in the context 
of lowered cell numbers, reflecting an increase in dopamine production in the surviving 
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dopaminergic neurons and implying an increase in DA release (Hornykiewicz, 1966, 
1993; Zigmond et al., 1990, 1993). Several studies have indeed shown an increase in 
dopamine production by the spared dopaminergic neurons (Alter et al., 1987; Hefti et al.., 
1980; Onn et al., 1986; Uretsky and Iversen, 1970; Zigmond et al., 1984). Of particular 
note is an increase in the ratio of tyrosine hydroxylase activity to dopamine levels as well 
as an increase in dopamine synthesis in spared dopaminergic neurons (Acheson and 
Zigmond, 1981; Agid et al., 1973; Altar et al., 1987; Bloom et al., 1969; Onn et al , 1986; 
Uretsky and Iversen, 1971; Wolf et al., 1989; Zigmond et al., 1984). The increased 
dopamine production and release in diminished cell numbers led to the conclusion that a 
major compensatory mechanism involves increased dopamine output by existing 
terminals (Zigmond et al., 1984) and/or by newly created terminals of surviving cells 
(Cochiolo et al, 2000). To our knowledge, our initial study (Cochiolo et al, 2000) was the 
first to present ultrastructural evidence of increased synaptic output in spared neurons as 
a compensatory mechanism to increase dopamine levels in response to the neurotoxin, 
MPTP. This compensatory mechanism, by itself or in combination with other 
mechanisms, is effective in maintaining survival of the individual until dopaminergic 
neuronal death exceeds a critical threshold: 70-80% of striatal nerve terminals and 50-
60% of substantia nigra pars compacta pericaryons (Bernheimer et al., 1973; Riederer 
and Wuketich, 1976). 
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Aims of the Time-Course Study of MPTP-Treated C57BL/6 Mice 
The overall focus of the present time-course study was on the MPTP-induced 
ultrastructural damage and compensatory mechanisms that allow the C57 mouse to 
recover from the array of PD-like changes that occur in response to MPTP. It is likely 
that analogous compensatory mechanisms during the preclinical phase of human PD 
delay the appearance of the cardinal symptoms until a threshold is reached whereby these 
mechanisms are no longer effective. Hence, a better understanding of the mechanisms 
involved in mouse recovery may lead to the development of new detection and 
therapeutic approaches to stave off the debilitating symptoms of PD. 
Our laboratory (Cochiolo et al., 2000) previously produced evidence for a structural 
and functional repatterning of dopaminergic neurons that allowed them to compensate for 
the loss of neighboring cells to effect long-term survival of the individual Observations 
3,7, and 21 days following MPTP administration were made in the present investigation 
to search for the presence of dark terminals to determine whether they are indicative of 
degeneration or of recovery. Our results lend support to the notion that dopaminergic 
neurons spared from destruction compensate for the loss of other dopaminergic neurons 
by increasing signaling functionality through increased vesicle production in terminals 
and the production of new terminals. Indirect evidence was also accumulated that 
indicated regenerative events either via sprouting from or division of existing cells or the 
entrance of new dopaminergic neurons into the striatum. 
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MATERIALS AND METHODS 
Middle-aged (6-8-month-old) male C57BL/6 mice, obtained from Simonsen Labs 
(Gilroy, California), were housed one per Plexiglas cage with free access to food and 
water in a colony room maintained at 23 ± 1° C. Control mice were injected with 0.85% 
saline Mice were given a single subcutaneous injection of a 35 mg/kg dose of the 
hydrochloride salt of MPTP. MPTP-treated mice were sacrificed 3 (5 mice), 7 (5 mice), 
or 21 (2 mice) days post-injection. All animals were anesthetized subcutaneously with 
Phenobarbital and perfused via the left atrium with heparin (10 units/ml 0.85% saline) 
and then 2.5% (w/v) paraformaldehyde and 3% (w/v) glutaraldehyde in 0.05 M sodium 
cacodylate buffer, pH 7.4. The brains were immediately removed from their skulls and 
striatal tissues dissected out and diced. These tissue fragments were bathed in the 
primary fixative for 5 days and postfixed in 2% (w/v) osmium tetroxide and 1.25% 
potassium ferrocyanide in sodium cacodylate buffer, pH 7.4, for 2 hours. They were 
prestained en bloc with 2% aqueous (w/v) uranyl acetate, dehydrated in a graded series of 
ethyl alcohol, and infiltrated with and embedded in Epon 812 resin. The blocks were thin 
sectioned (100-120 nm) on a Leica Ultracut UCT ultramicrotome. Sections were post-
stained with 2% uranyl acetate and Reynold's lead citrate and viewed on a Leo 912AB 
transmission electron microscope. 
To distinguish between the effects of MPTP and preparation artifacts, fixation quality 
was assessed in each region by observation of mitochondrial intactness and maintenance 
of periplasmic space volume. When any two of these features were absent, the brain 
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tissues from which the section was taken were discarded and the section was excluded 
from the study. 
RESULTS 
Degenerative Changes 
Severe deterioration of myelin sheaths was observed at each stage of the time course 
(Fig. 1 A-C,E, 2A-C, 3A-D). Gaps were detected between the plasma membrane and 
myelin sheath due to cytoplasmic shrinkage, the plasma membrane receding from the 
sheath, and the sheath pulling away from the axon (Fig. 1 A,C, 2A, 3 A). Separation of the 
laminae of the myelin sheath (Fig. 1 A,E, 2A-C, 3 A) was accompanied by electron-dense 
particles (Fig. 3D,E) that appeared to be myelin breakdown products. In axons that were 
clearly undergoing degeneration, these particles were also present in areas where 
unraveling had not yet occurred (Fig. 3D). Demyelination, observable at early stages as 
interruptions in the myelin sheath, exposed the plasma membrane to the neuropil (Fig 1 A, 
3A-D). Presumptive microglial processes were seen in close proximity to degenerating 
axons (Fig. 1 A). 
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F/g. 7. 3 days post-MPTP. 
A. Myelin sheath pulling away from 
axonal plasma membrane (*) and 
separation of laminae of myelin 
(white arrow). A microglial process 
occurs at the black arrow. B. 
Compression and tangling of 
cytoskeletal elements within an axon 
displaying slight myelin damage at 
arrows. C. Severe cytoplasmic 
shrinkage (*) and myelin breaks. D. 
Low density astrocytic processes 
(Ap) surrounding an interneuron (N) 
that displays cytoplasmic 
condensation and vacuolation. E. 
Damaged axons (Ax) showing 
unraveling of myelin adjacent to a 
degenerating interneuron (N). F. An 
interneuron (N) demonstrating 
nuclear (*) and cytoplasmic 
condensation, vacuolation (V), and 
peripheral blebbing (unlabeled 
arrow). The surrounding neuropil 
shows disruption and clearing. G. 
Axonal ghost (arrow) and more 
extensive region of clearing. Scale 
bar = 0.2 um in A and B; 2 urn in C; 
and 5 um in D-G. 
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MPTP-induced displacement and clumping of neurofilaments and microtubules 
occurred in conjunction with myelin unraveling (Fig. 2C) as well as in axons with 
apparently intact myelin, at least as revealed in the plane of section of the figure (Fig. 
IB). Mitochondrial swelling was common (Fig. IE, 2C) but was more frequent at 7 days 
post-MPTP injection than at 21 days. 
Electron-translucent areas occurred at all stages of the time course, maximally at 7 
days (Fig.lG) and generally much less so at 21 days (Fig. 3A-C), as deduced through 
consistent scans (not all shown) of large numbers of axonal and synaptic fields. Most of 
Fig. 2. 7 Jays post-MPTP. 
A. Extensive cytoplasmic clearing in the neuropil (*)• 
with damaged axons throughout. Enlarged space (SI) 
contains remnants of cytoplasm and is surrounded by 
myelin, indicating an early stage of cellular clearing. 
The space at S2 is similar but has been subjected to a 
greater degree of demyelination so that only a faint 
boundary of the original degenerating neuron is 
visible. B. Degenerative neurons with dark 
inclusions (large arrows) and large lysosomes with 
dense cores (small arrows). C. Impaired axons (Ax) 
displaying disruption of cytoskeletal elements 
(surrounding *), myelin unraveling (black arrow), and 
dense particles at the sites of unraveling (white 
arrow). Mitochondrial damage is also observed (M). 
D. A cell with morphology clearly identifying it as a 
degenerating interneuron (N) with condensed 
chromatin and small vacuoles. Cleared regions 
around the neuron are prevalent. E. Higher 
magnification view of the axonal segment contiguous 
with the axonal hillock of the interneuron in the 
previous figure. The configuration of the cytoskeletal 
elements clearly indicate that the cell is a neuron. 
Cleared regions surround the axon (*). F.-H. 
Examples of apoptotic appearing interneurons. Scale 
bar = 5 um in A; 2 um in B; 1 um in C; 10 urn in D-
E, 1 um in F, and 5 um in G-H. 
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Fig. 3. 21 days post-MPTP. 
A. Clearing in the neuropil at advanced stage of cellular elimination, where myelin is no longer visible 
around the space (S3); the original cell shape has still been maintained producing a cellular ghost. Also 
present are breaks in the myelin sheath (arrows) and disorganization and disappearance of axonal contents 
(arrowhead). B. Breaks in and unraveling of the myelin sheath and disruption of the cytoskeleton in 
region of cytoplasmic vacuolation. C. Damaged axons displaying all forms of degeneration. 
Accumulation of electron-dense deposits and membranous structures in the axon (inset). D. Electron-
dense particles (arrow) in nearly completely reabsorbed cell. Nearby is a degenerative axon (Ax) showing 
myelin interruption, cytoplasmic shrinkage, and cytoskeletal disruption (arrowhead). E. Higher 
magnification view of an area in Fig. 3D revealing congealment of the myelin sheath and subsequent 
granulation. Scale bar = 5 p.m in A; 0.5um in B; 5 urn in C; 1 um in C inset; 0.5 um in D-E. 
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these areas were clearly the result of progressive neuronal degeneration, as various stages 
of formation of cellular "ghosts" were evident (Fig. 1G, 2A,E, 3A,C,D). For example, in 
Fig. 2 A, the cell at SI displays obvious protoplasmic and myelin degradation, but the 
myelin is still visible enough to make out the cell outline. The cell at S2 of Fig 2 A 
progressed further, deteriorating nearly to the point of complete cellular clearing. The 
cell at S3 in Fig. 3 A vanished entirely, but the maintenance of the shape of the cleared 
region indicates the former presence of a cell. Some of these ghosts still contain 
remnants of myelin (Fig. 3D), in the form of the electron-dense particles mentioned 
above, lending support to our designation of the spaces as cellular in origin. Some 
electron-transparent regions, however, appear to be occupied by astrocytes, whose 
processes have intruded into regions vacated by cellular clearing (Fig ID). Our methods 
of assessing the degree of degeneration within the large striatal expanse may be prone to 
undersampling, but our observations are consistent with those of other studies employing 
immunohistochemical and biochemical methods. 
Extremely dense cell bodies of questionable identity occurred in highest number at 7 
days and declined in frequency by 21 days. Through observations of alternative planes of 
section, we were able to capture images of unmistakable neuronal morphology in cells of 
a similar nature (Fig. 2D). These cells bore axonal processes and thus were concluded to 
be interneurons undergoing degeneration. Degenerative processes included various 
stages of chromatin condensation in (Fig. IF, 2D, 2F-H) and vesiculation of (Fig. 2F-H) 
their large nuclei. The cytoplasm was in a condensed state containing distended and 
dense lysosomes (Fig. 2B) and swollen and distorted mitochondria with disrupted cristae 
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and cleared matrices both within the cell body (Fig. 2B) and the axon (Fig. 4A,B). 
Axonal cytoskeletal displacement was also evident (Fig. 4A,B)-
Cytoplasmic deterioration progressed to an even more highly condensed condition 
lacking any recognizable organelles and with especially dense blotches (Fig. 2B). 
Vacuolation was extensive on the periphery of the cells (Fig. 2F-H). Astrocytic 
processes (Fig. ID) and areas of clearing occurred both interior (Fig. 2D-E) and exterior 
to these cells. 
Dark Axon Terminals and Interneurons 
Axon terminals of dopaminergic neurons were darkened as a result of their high 
density of synaptic vesicles (Fig. 5-10). They were positioned extensively en passant. 
Darkened en passant boutons were most abundant in our sections in the spared fibers of 
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the 7-day samples (Fig. 5-8, 10), but they were still present in the 21-day samples (Fig. 
Fis. 5. Dark terminals at ? 
days post-MPTP. 
A. Low magnification view of 
dark terminals (arrows). B. 
Higher magnification view of 
two of the dark terminals 
(arrows) in Fig. 5A, in which 
dense vesicles are visible. The 
labeled mitochondrion (M) has 
maintained its integrity and 
appears to be part of the same 
cell as the lowermost dark 
bouton, which is synapsing on 
the dendrite at D. Scale bar = 5 
urn in A; 0.5 urn in B. 
9A,B). Multiple (mostly paired) and perforated synaptic densities occurred in the dark 
terminals (Fig. 8A,B). We made an effort to visualize the axons that the dark boutons 
flanked to determine whether these boutons were associated with healthy or damaged 
17 
axons. The extreme curvature of axons in the vicinity of these boutons made their 
detection challenging. Several were identified and revealed to have dark boutons 
associated with intact axons lacking any of the morphological features that characterized 
injured axons (Figs. 6A,B). A convincing example is shown in Fig. 6A where a 
transverse section through a parent axon includes a dark terminal. It is clear that the axon 
is healthy, lacking any shrinkage, autolysis, or microtubule and neurofilament 
disarrangement or tangling. 
Fie. 6. Dark terminals at 7 days post-MPTP. 
A. Dark en passant bouton with arrow 
pointing to synaptic vesicles within an axon 
(Ax) containing an undamaged 
mitochondrion (M). The region of extreme 
| electron density is a face view of the pre-
synaptic density. B. Two populations of 
vesicles (V) forming electron-dense regions 
within probable separate dark terminals of a 
single healthy axon (Ax) bearing an 
undisrupted cytoskeleton and mitochondria 
(M). Scale bar = 0.5 u.m. 
As we observed previously, parallel arrays of microtubules appeared to traverse the 
neuropil (Fig. 7 A). Because confining cell membranes could rarely be seen, these 
microtubules seemed to be located external to cells. In agreement with our previous 
study, some of these arrays were seen in association with en passant boutons, confirming 
that they were located in axons (Fig. 6A). Unrecognized previously, however, some of 
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these arrays were clearly in interneuronal dendrites synapsed on by dark terminals (Fig. 
5B, 7B). 
Fig. 7. Dark terminals synapsing on healthy 
interneuron at 7 days post-MPTP. 
A. Cytoskeletal elements seemingly running 
through region with unidentifiable cellular 
boundaries. This structure resembles the 
dendrites of healthy interneurons as well as the 
axons from which dark terminals branch. B. 
Healthy interneuron (N) with abundant 
endoplasmic reticulum (ER) arranged both in 
parallel array and in a more disorganized 
fashion. Healthy mitochondria (M) are located 
throughout. Dark terminals (DT) are synapsing 
proximal to the cell body onto a primary 
dendritic process (D). The dark terminals were 
identified by viewing them at higher 
magnification. The neuropil surrounding this 
healthy neuron shows no clearing or damage 
1 Scale bar = 0.5 um in A; 5 um in B. 
We observed many cases of the darkened en passant terminals synapsing on dendrites 
of healthy (spared) interneurons (Fig. 7B). Spared interneurons were relatively large with 
abundant parallel and randomly arranged rough endoplasmic reticulum (Fig. 7B,10). The 
cells also contained healthy mitochondria (Fig. 7B,10). Hence, it is reasonable to assume 
that the majority of dendrites on which dark terminals synapsed but whose cell bodies 
were not visible in section also belonged to healthy interneurons. 
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Fis. 8. Dark terminals synapsing on 
dendrites at 7 days post-MPTP. 
A. Dark terminal (DT) with densely 
packed vesicles. The terminal is 
synapsing (S) on a dendrite (D) with 
darkly staining post-synaptic density. 
M, mitochondrion. B. Dark terminal 
with a perforated synapse (S) 
composed of deeply staining post- and 
• j l pre-synaptic densities. Scale bar = 0.5 
\im. 
21-Day Axonal Fields 
There was a dramatic increase in fields of healthy axons at the 21-day stage (Fig. 11). 
Evident was a jigsaw puzzle pattern of abutted axons with minimal extracellular space. 
The myelin sheath of the axons appeared to be tightly wound, although with slight 
disruptions attributable to imperfect fixation. Fields of more narrow, unmyelinated axons 
were also most abundant in the 21-day samples. 
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Fig, 9. Dark terminals svnapsing on dendrites at 21 days post-MPTP 
A. Dark terminal (DT) with densely packed vesicles synapsing (S) on the 
dendrite at D. M, mitochondrion. B. Dark en passant terminals with densely 
packed vesicles (V) an d healthy mitochondrion (M). The synapse (S) of the 
uppermost terminal is clearly perforated. Scale bar = 1 ^m. 
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Fig. 10. Dark terminals svnapsing on interneuron at 7 days post-MPTP. 
Healthy interneuronal cell body (N) with ER and mitochondria (M) throughout the cell. 
A high number of dark terminals (DT) are synapsing (S) onto dendrites (D) in close 
proximity to the cell body of the interneuron. Insets are of higher magnification views of 
portions of the montaged image on the right. Scale bar = 2 urn in large image and 1 um 
in insets. 
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Fig. 11 Axon fields at 21 days post-MPTP. 
A-E. Fields of healthy axons with minimal clearing. Relative 
to other stages, there is an increase in the number of small 
diameter fibers. Scale bar =10 \im. 
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DISCUSSION 
Damage Induced by MPTP 
Axonal degeneration was evident at all stages of the time course in the form of myelin 
separation, demyelination, localized cytoplasmic shrinkage, mitochondrial disruption, or 
microtubule and neurofilament disturbance. The MPTP-induced striatal degeneration 
observed in response to MPTP insult was comparable to that reported in other 
ultrastructural studies (Forno et al., 1994; Lewandowska et al., 1999; Rapisardi et al., 
1990). The changes observed 3 days post-MPTP injection were similar to those at the 1-
day post-injection stage observed in our earlier study (Cochiolo et al., 2000). By 7 days, 
more extensive degeneration occurred, including a greater frequency of mitochondrial 
damage, of axonal ghosts, and of degenerative interneurons. Our findings at the 7-day 
stage correlate with the progressive disappearance of TH-positive fibers in the striatum, 
which Sundstrom et al. (1987, 1988) found to reach maximal levels 7 days after 
treatment. Although areas of damage and clearing can be located at 21-days post-
injection, the striatal ultrastructure appears to be much healthier than that observed at 3 
and 7 days. 
Our finding of maximum mitochondrial degeneration at 7 days is in accord with 
studies in which mitochondrial dysfunction, particularly of complex I of the electron 
transport chain, has been implicated to contribute to the pathological progression of PD 
(Shults, 2004). MPTP has been shown to accumulate within the mitochondria as MPP+ 
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(Ramsay et al., 1986), which, through its interaction with complex I, causes a reduction 
in mouse striatal and midbrain ATP levels (Chan et al., 1991). This reduction in 
conjunction with the increased generation of reactive oxygen species (Cleeter et al., 1992; 
Hasegawa et al., 1990; Rossetti et al., 1988) most likely results in the ultrastructural 
aberrations that befall mitochondria and the rest of the cell. The existence in the same 
thin section of both unaltered mitochondria in healthy cells and comprised mitochondria 
in damaged cells indicated that the damage observed was not a fixation artifact. 
Dark Terminals 
In our previous study, we concluded that the abundant and densely vesiculated 
boutons, called dark degenerative boutons by others (Linder, 1987,1995), were 
associated with large, healthy axons and, therefore, were unlikely to be degenerative 
(Cochiolo et al., 2000). The association of the terminals with healthy axons and the 
increased number and packing of vesicles 1 day post-MPTP injection led us to deduce 
that these surviving terminals increased their dopaminergic output to compensate for the 
overall loss of neurons. It could be argued that these darkened vesiculated terminals were 
an initial step in a degenerative process leading to darkened boutons lacking vesicles, as 
reported by Linder et al. (1987, 1995). However, the "condensed" terminals at the 1-day 
post-injection stage reported by Adams et al. (1989) contained dense and packed vesicles, 
similar to our findings at that stage (Cochiolo et al, 2000). Similarly, darkened 
vesiculated terminals persisted until 21 days in our present time course, failing to reveal 
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any vesicle elimination. Throughout the time course, these terminals were associated 
with healthy axons and synapsed on healthy dendrites, supporting the conclusion that 
they are not degenerative. We saw not a single case in which dark terminals synapsed on 
unhealthy neurons. Instead they appeared to be part of a compensatory increase in 
signaling efficacy responsible for the initial recovery of the mouse from MPTP toxicity. 
If the dark terminals were indicators of neuronal degeneration, one would expect the 
time course to reveal an increase in dark terminals associated with degenerative axons 
Instead, we found in this and our previous study (Cochiolo et al., 2000) that the axons in 
continuity with the dark terminals were undamaged. Moreover, one would also expect 
rapid elimination of dark terminals as cells died and were cleared away. The persistence 
of dark terminals in the midst of striatal degeneration and clearing argues against the 
degeneration alternative. Cells clearly had died leaving substantial spaces, presumably as 
a result of reabsorption of cellular contents by microglia, while dark terminals remained 
intact. We, therefore, continue to maintain that the darkening processes are agents of 
recovery rather than of degeneration. 
Early and Late Compensatory Mechanisms 
We hypothesized that neurons spared from MPTP-induced death increased dopamine 
levels high enough to maintain signaling. Within the first 2-3 days post-injection, mice 
exhibit clear behavioral deficits; thereafter, the deficits diminish and the animals regain 
normal behavior (Hallman et al, 1985; Reinhard et al., 1988; Ricaurte et al, 1986; 
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Sundstrom et at., t990). Ultrastructural abnormalities, however, persisted in our mice for 
three weeks, while evidence of sprouting or regeneration was not observed until this 
point. This distinction suggests that both acute and longer term compensatory 
mechanisms are involved in the recovery process. 
There is strong evidence that after neurotoxin lesioning of the mouse substantia nigra 
pars compacta (SNc), dopaminergic neurons from the SNc or other regions of the brain 
sprout to reinnervate the dorsal striatum (Anglade et at., 1996; Blanchard et at., 1995, 
1996; Finkelstein et at., 2000; Ho and Blum, 1998; Ingham et at., 1996, 1998; Kerns et 
at., 1992; Leonard et at., 1993; Mitsumoto et al., 1998; Parish et al., 2001; Pickel et at., 
1992; Thomas et at., 1994; Wong et al., 1997). In approximately 4 months, most of the 
dopaminergic terminals in the striatum were found to be newly formed (Finkelstein et al., 
2000; Stanic et at., 2003) and to bear features, including amassing synaptic vesicles, that 
signified a greater ability to produce, store, and release dopamine in comparison to the 
predeath capacity of the terminals that did not survive lesioning (Stanic et at., 2003). 
Regeneration became apparent in the striatum by the identification of hypertrophic 
dopamine transporter-immunoreactive terminals about 30 days after lesioning (Stanic et 
al., 2002,2003), and it continued for up to 7 months (Blanchard et al., 1996). Because 
C57 mice recover behaviorally within seven days (Donnan et al., 1987; Tillerson and 
Miller, 2003; Willis and Donnan, 1987) and increase striatal dopamine levels 
significantly within the first 30 days (Hallman et al., 1985; Reinhard et al., 1988; Ricaurte 
et al., 1986; Sundstrom et al., 1990), some other mechanism must exist to allow survival 
following the loss of dopaminergic neurons before the reinnervation period. Likely 
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candidates, as reported here, are the formation of new en passant terminals and the 
elevation in dopamine production by existing terminals, as indicated by heightened 
synaptic vesicle density. 
Nigrostriatal synaptic terminals most commonly form contacts with dendritic spines 
and shafts (Anglade et al., 1996; Descarries et al , 1996; Freund et al., 1984; Groves et 
al., 1994; Hanley and Bolam, 1997; Ingham et al., 1998; Zahm, 1992). Of the new 
contacts made following lesioning, the majority are proximal to the cell body (Ingham et 
al., 1996, 1998). The dark terminals in our investigation also synapsed proximal to 
interneuronal cell bodies. More proximal synapses are thought to have a more substantial 
impact in target neurons than distal synapses (Pickel et al., 1992). Hence, not only are 
the dark terminals apparently increasing dopamine release, their proximal location 
enhances the efficiency of signaling. 
It is our conclusion that the dark vesiculated terminals contribute to mouse recovery 
from MPTP by increasing the efficacy of dopamine signal transmission in the spared 
neurons. Increased functional capacity of the synapse due to an increase in synaptic 
vesicles in boutons has been observed in other studies (Lnenicka et al., 1991; Pierce and 
Lewin, 1994; Sasaki and Iwata, 1996). Other researchers have found that spared 
dopaminergic neurons of the SNc did not increase their firing rate or pattern of firing 
(Hollerman and Grace, 1990; Pucak and Grace 1991). Hence, the increase in dopamine 
production by spared cells is due to an increase in the net amount of dopamine released in 
response to each action potential (Stachowiak et al., 1987; Synder et al. 1990). Evidence 
for a functional significance of increased dopamine output comes from studies 
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elucidating the ability of dopaminergic neurons to inhibit cholinergic interneurons after 
insult to the dopaminergic pathway (Grewaal et al., 1974; Guyenet et al., 1975; 
MacKenzie et a l , 1989). 
Our ultrastructural results as well as the immunocytochemistry results of others 
(Jackson-Lewis et al., 1995) support the role of increased synaptic output in surviving 
neurons as an early compensatory response. At 7 days post-injection, when recovery in 
animal behavior has been reported (Rozas et al., 1998) in spite of significant depletion of 
dopamine (70-90%) (Rozas et al., 1998; Sundstrom et al., 1988), we observed an increase 
in the frequency of dark terminals. This set of results is consistent with our hypothesis 
that the increased frequency of dark terminals aids the animal in its recovery despite 
significant ultrastructural deterioration. 
Our results indicating a lack of sprouting at 7 days correlate with studies reporting 
sprouting to occur between 14 days (Ho and Blum. 1998) and 210 days post-injection 
(Bezard et al., 2000), making it unlikely for sprouting to play a role in the acute phase of 
recovery. At the 7-day post-injection point, when sprouting was absent and the 
degenerative effects of MPTP were most apparent in this and other studies (Sundstrom et 
al., 1988), dark terminals were most frequent and associated with healthy axons. From 
these results, it is logical to infer that the dark terminals act to stabilize the intact circuitry 
until sprouting can occur. The notion that dark terminals are agents of the compensatory 
response that allows the animal to survive the MPTP challenge until sprouting can occur 
is further supported by studies reporting no change in TH-positive cell bodies in the SNc 
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and statistically significant changes in TH-positive fiber densities, and thus the number of 
axons in the striatum, only at 24 days post-injection (Mitsumoto et al., 1998). 
It is likely that the increase in synaptic output guides the synaptic remodeling that later 
occurs (Meredith et a l , 2000; Meshul and Allen 2000; Meshul and Tan 1994; Stantic et 
al., 2003). A marked decrease in the volume of cleared regions, which occurred at the 
21-day stage, is most readily explained by sprouting and/or regeneration. Sprouting and 
regeneration are likely to play a prominent role in longer term compensation, whereas the 
increase in dopamine output per cell by spared (or newly formed) boutons plays a role in 
early stage compensatory responses. This model of recovery is based on the decline of 
dark terminal frequency at 21 days accompanied by a conspicuous increase in healthy 
fields of axons as well as by the well documented increase in overall tissue dopamine 
levels at this time (Hallman et al., 1985; Reinhard et al., 1988; Ricaurte et al., 1986; 
Sundstrom et al., 1990). 
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